Healthcare Business

AbbVie Delivers on Promise of Higher Dividend and Stronger Stock Buybacks

AbbVie Inc. (NYSE: ABBV) is joining the companies raising their shareholder rewards. The pharmaceutical products maker has announced how it will further commit to previously forecast moves. AbbVie is raising ...
Read Full Story »

Moleculin Biotech Explodes on Breakthrough Cancer Treatment

Moleculin Biotech Inc. (NASDAQ: MBRX) watched its shares climb on Thursday after the company announced a new breakthrough for cancer treatment. While this is broad and could hold multiple applications, ...
Read Full Story »

Why AMAG Pharmaceuticals Is Soaring

AMAG Pharmaceuticals Inc. (NASDAQ: AMAG) saw its shares skyrocket early on Thursday after the company announced that it received an FDA approval. Specifically, the company said that the FDA approved ...
Read Full Story »

Why Tetraphase Pharmaceuticals Is Getting Cut in Half

Tetraphase Pharmaceuticals Inc. (NASDAQ: TTPH) saw its shares get cut in half on Wednesday after the firm provided an update on its late-stage clinical trial for the treatment of complicated ...
Read Full Story »

Top Analyst Has 3 Large Cap Biotechs to Buy as Massive Selling Subsides

While the market has bounced back smartly over the past few sessions, one thing is for sure: the baby was tossed out with the proverbial bathwater in many sectors. Nowhere ...
Read Full Story »

Why Catabasis Is Tuesday’s Biggest Winner

Catabasis Pharmaceuticals Inc. (NASDAQ: CATB) saw its shares skyrocket on Tuesday after the firm announced new results from its Duchene muscular dystrophy (DMD) study with edasalonexent. Overall the trial showed ...
Read Full Story »

BioXel Gears Up for IPO

BioXel Therapeutics has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). No pricing details were given in the filing, but the ...
Read Full Story »

Is This the End of Axovant?

Axovant Sciences Ltd. (NASDAQ: AXON) saw its shares take a big step back to start out the week after the company announced that there would be some changes at the ...
Read Full Story »

Short Sellers Can’t Make Up Their Minds on Major Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Major Biotechs See Rising Tide of Short Interest

The short interest data are out for the most recent settlement date, January 31. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »

CVS Earnings Yield Boosts to Starting Pay, Benefits

Pharmacy giant CVS Health Corp. (NYSE: CVS) announced this morning that the company will lift its starting hourly wage from $9 to $11 beginning in April and introduce other improvements ...
Read Full Story »

JPMorgan Likes Big Cap Pharmaceutical Stocks as Market Volatility Jumps

For years pharmaceuticals were one group considered good for “widows and orphans” as they provided safety and consistent and rising income via dividends. Then came the brutal 2016 political season wherein ...
Read Full Story »

Why Theravance Biopharma Shares Are Soaring

Shares of Theravance Biopharma Inc. (NASDAQ: TBPH) saw a solid gain on Wednesday after the company announced a global collaboration with Johnson & Johnson (NYSE: JNJ) subsidiary, Janssen Biotech. The ...
Read Full Story »

Why Allergan Continues to Slide

When Allergan PLC (NYSE: AGN) reported its most recent quarterly results before the markets opened on Tuesday, the company said that it had $4.86 in earnings per share (EPS) on ...
Read Full Story »

Bristol-Myers Squibb Earnings, Trial Results Not Enough to Please Investors

Bristol-Myers Squibb Co. (NYSE: BMY) reported fourth-quarter and full-year 2017 results before markets opened Monday. For the quarter, the drug maker posted adjusted diluted earnings per share (EPS) of $0.68 ...
Read Full Story »